- GYRE Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
DEF 14A Filing
Gyre Therapeutics (GYRE) DEF 14ADefinitive proxy
Filed: 16 Apr 10, 12:00am
[TARGACEPT, INC. LETTERHEAD]
April 16, 2010
VIA EDGAR
Filing Desk
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re: | Targacept, Inc. Definitive Proxy Materials |
Ladies and Gentlemen:
On behalf of Targacept, Inc. (the “Company”), accompanying this letter for filing please find: (i) the definitive notice of annual meeting, proxy statement and form of proxy (the “definitive proxy materials”) to be furnished by the Company to its stockholders in connection with the Company’s 2010 Annual Meeting of Stockholders scheduled for June 10, 2010, as required pursuant to Rule 14a-6(b) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”); and (ii) the Schedule 14A cover page required pursuant to Rule 14a-6(m) promulgated under the Exchange Act.
The Company intends to make the definitive proxy materials available to its stockholders on or about April 16, 2010.
Sincerely, | ||
Targacept, Inc. | ||
By: | /s/ Peter A. Zorn | |
Peter A. Zorn | ||
Senior Vice President, Legal Affairs, General | ||
Counsel and Secretary |